Alison joins the ABPI from Innovex where she held a series of top management roles, including running their UK business.
Her new role will be to drive the ABPI’s value imperative, which aims to reframe thinking around medicines in order to better reflect the benefits they bring.
She will work with industry, NICE and the NHS to drive change in the way new medicines are appraised and perceived moving from a cost-based to a value-based approach.
Before becoming managing director at Innovex, Alison was operations director for the Clinical Research and Health Management division and prior to this had a variety of roles during 15 years at GlaxoSmithKline.
A pharmacist by training, she graduated from Nottingham University and began her career in hospital pharmacy.
Alison said: “The question of value is a vital topic for the pharmaceutical industry. People tend to thinks in terms of immediate cost rather than seeing long-term value. “A key part of my role will be to develop better understanding and shift that debate but it will also be focussed on very practical issues like the appraisal process.”
David Fisher, commercial director of the ABPI, said: “Alison is a key appointment. The ABPI’s new strategy is to focus on four industry imperatives – value, innovation, trust and access.
“Alison will be leading the work around value and has a key role to play in ensuring its success which will feed into the long-term health of the pharmaceutical industry in the UK.”
NOTES TO EDITORS:
For further information, please contact the ABPI press office: 020 7747 1410.